Psychedelic-Based Treatments

Mechanism

Related News

Compass Pathways highlights FDA Breakthrough designation as Trump orders faster psychedelic reviews

May 18, 2026

Compass Pathways said COMP360 for treatment-resistant depression retains FDA Breakthrough Therapy designation as it advances in phase 3. A Trump executive order also directs faster federal review of psychedelic drugs with breakthrough status.

Studies point to new psychedelic-based depression treatments

Apr 12, 2026

New findings on psychedelic-based depression treatments included a UK DMT trial in 34 adults and a mouse study of modified psilocin compounds with fewer hallucinogenic-like effects.